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Abstract
Background & Aims—Decreased bone mass is common in children with inflammatory bowel
diseases (IBD); however, fracture risk is unknown. We sought to evaluate fracture risk in children
with IBD as compared to unaffected controls and determine whether this risk is affected by
geographical region (a proxy for sun/vitamin D exposure) and oral steroid use.
Methods—We identified cases of Crohn's disease (CD) and ulcerative colitis (UC), less than 20
years of age, using administrative data from 87 health plans. Each case was matched to 3 controls,
on the basis of age, gender, and geographical region. We identified fractures in cases and controls
using ICD-9 diagnosis codes, and measured oral steroid exposure using NDC codes.
Results—The study included 733 children with CD, 488 with UC, and 3287 controls (mean age
15 years). IBD was not associated with a higher risk of fracture at any site [CD OR 0.8 (95% CI
0.6-1.1; UC OR 1.4 (95% CI 1.0-2.1)] or at multiple sites [CD OR 0.8 (95% CI 0.4-1.7; UC OR
0.4 (95% CI 0.1-1.4)]. Among IBD patients, we did not identify any significant differences in the
fracture rate between those residing in the Northeast/Midwest versus the South (OR 1.3, 95% CI
0.8-2.2). Steroid exposure was not associated with the occurrence of fractures (p=0.6).
Conclusions—Children with IBD are no more likely to have experienced a diagnosed fracture
than age, sex, and gender-matched controls.
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Background
Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel
diseases (IBDs), are chronic, idiopathic conditions of the gastrointestinal tract that affect
between 1 and 1.5 million Americans.1-3 Nearly ¼ of cases have onset during the childhood
or adolescent years. Both conditions are associated with high costs4, substantial disease-
specific morbidity, 5 and decreased quality of life6, 7. Additionally, patients often experience
one or more nutritional complications including osteoporosis, growth failure, delayed
puberty, anemia, and micronutrient deficiencies8.
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A number of studies published over the last decade have described a high prevalence of
osteopenia and osteoporosis in affected adult patients. A recent technical review published
by the American Gastroenterological Association estimated the overall prevalence of
osteoporosis to be 15% in the adult IBD population.9 Furthermore several population based
studies have shown that IBD is associated with an increased risk of fractures, particularly
fragility fractures. A Danish study used hospital discharge data to determine the relative risk
of fracture requiring hospitalization in 7072 patients with Crohn's disease and 8323 patients
with ulcerative colitis compared to age and gender matched controls. This study found a
mildly increased risk of fracture for CD [RR=1.19 (95% CI. 1.06-1.33)]. The association for
UC was not statistically significant.10 A major limitation to this study was reliance on
hospital discharge data. Thus, outpatient fractures were not included. A second population
based study in Manitoba, Canada used administrative data to compare the rates of both
inpatient and outpatient fractures in IBD patients versus age, gender, and geographically
matched controls. This study found a RR of 1.41 (95% CI 1.27-1.56) for IBD with no
differences between CD and UC.11 In the United States, a series of population-based studies
in Olmsted county, MN, demonstrated a non-statistically significant increased risk of
osteoporosis-related fractures (RR 1.4, 95% CI 0.7 to 2.7) but not total fractures in Crohn's
disease patients.12 Results showed a similar non-significant increased risk of osteoporotic
fracture in UC patients compared to controls.13 A final study using data from the General
Practice Research Database in the UK also described a small excess risk of fractures in IBD
patients, most prominent in the elderly.14 Taken together, the results of epidemiological
studies in adult populations suggest that patients with IBD have an increased risk of fracture,
compared to the general population.
Whether children with IBD have an increased risk of fracture is largely unknown. Because
the childhood and adolescent years are the time during which peak bone mass is attained, it
is no surprise that decreased bone mass (a surrogate endpoint) has been reported in children
with IBD.15-18 However, the extent to which decreased bone mass leads to increased
fractures (the clinical endpoint) remains unknown. Based on differences in bone physiology
between children and adults, it is reasonable to suspect that effects of IBD on skeletal health
may differ in children and adults.19 Therefore, rigorous epidemiological studies of fracture
risk in pediatric patients with IBD are needed.
In addition, the identification of modifiable risk factors for fracture is also necessary to
inform screening and prevention guidelines. Such potential risk factors in the IBD
population include corticosteroid treatment, which has been associated with diminished bone
mineral density,16, 20 and vitamin D deficiency.21, 22
The objectives of this study were 1) To determine whether children with IBD are at
increased risk for fracture, compared to unaffected controls, and 2) To determine whether
geographical region (a proxy for sun/vitamin D exposure) and oral corticosteroid use are
associated with fractures among children with IBD.
Methods
Study Design and Data Source
We performed a cross-sectional study, analyzing the inpatient and outpatient insurance
claims contained within the PharMetrics Patient-Centric Database (IMS Health, Watertown,
MA) for the two year period January 1, 2003 through December 31, 2004. This longitudinal,
patient-level database that pools together claims from 87 different health plans in 33 states
has been reported to be representative of the national commercially-insured population on a
variety of demographic measures, including geographic region, age, gender, and health plan
Kappelman et al. Page 2













type23 and has been used in previous epidemiological studies of inflammatory bowel
disease. 3, 4
Patient Selection
All individuals in the database less than 20 years of age with continuous health plan
enrollment during the study period were eligible for inclusion in this analysis. We identified
cases of CD and UC using a previously reported definition based on administrative data.3
This definition included patients with at least 3 health care contacts, on different days,
associated with an International Classification of Diseases, 9th Revision, Clinical
Modification diagnosis code for CD (555.xx) or UC (556.xx), or patients with at least one
claim for CD or UC and at least 1 pharmacy claim for any of the following medications:
mesalamine, olsalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine,
infliximab, adalimumab, or enteral budesonide. For patients who had claims for both CD
and UC, disease assignment was made according to the majority of the last 9 claims. For
each case, we randomly selected up to 3 non-IBD controls from within the same health plan,
matched on the basis of age (3 year increments), gender, and geographic region.
Identification of fractures
For both cases and controls, we identified claims for fractures occurring at each of the
following sites using ICD-9 diagnosis codes: ankle, clavicle, foot, hand, humerus, femur,
radius, skull, tibia, and vertebral. Prescriptions for oral corticosteroids (prednisone,
prednisilone, methylprednisilone) were identified using National Drug Codes.
Statistical Analysis
We first determined the prevalence per 100,000 of fractures occurring at each site in the
selected cases and controls. Similar analyses were performed for fractures occurring at any
site and at multiple sites. Next, to compare the prevalence of fractures in IBD patients,
relative to controls, we computed prevalence odds ratios using logistic regression. Each
analysis was performed for IBD overall, and for CD and UC independently. Additionally,
we performed a sub-analysis of the prevalence and odds ratios of fractures occurring at any
site, after stratifying by age group (< 12 years, 12-17 years, and >17 years).
Among cases, we then compared the risk of fracture among patients residing in the South
(expected low prevalence of vitamin D deficiency) to that in patients residing in the
Northeast and Midwest (higher expected vitamin D deficiency) using logistic regression to
control for corticosteroid exposure. Additionally, to compare the risk of fracture in cases
versus controls residing in different regions, we also performed a sub-analysis of the
prevalence and odds ratios of fractures occurring at any site, after stratifying by
geographical region (Northeast/Midwest, South, West). Finally, we compared fracture risk
by corticosteroid exposure using Student's t test and linear regression to control for
geographical region.
All statistical analyses were performed using SAS version 9.2 (Cary, NC), and the study
protocol was granted exemption from review by the Institutional Review Boards at the




Our study population included 737 cases of pediatric Crohn's with 1,997 controls, and 488
cases of UC with 1,310 controls (Overall 1242 cases of IBD and 3353 controls).
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Characteristics of included individuals are shown in Table 1. The mean age for both disease
groups and controls was 15 years. Forty-four percent of CD patients and 47 % of UC
patients were female. Each of the 4 major U.S. census regions was adequately represented.
Prevalence and risk of fractures
The prevalence per 100,000 population of fractures at any site and multiple fractures
(different sites) for cases and controls are shown in Table 2. For CD and total IBD, there
were no differences in the proportion of fractures occurring in cases versus controls (95%
confidence intervals all cross 1). For UC, there was a nonsignificant trend towards increased
fracture risk (OR 1.4, 95% CI 1.0-2.0) in cases. When analyzing the occurrence of multiple
fractures (different sites) sites, there were no significant differences between cases of CD,
UC, or total IBD versus their respective controls.
Fracture risks by site are displayed graphically in Figure 1. As illustrated, the confidence
intervals for prevalence odds ratios for each site all crossed 1, indicating no significant
differences between cases and controls. However, there was a strong trend towards
increased risk of vertebral fractures (OR 2.7, 95% CI 0.8-10.8). For CD, the effect estimate
was even higher (OR 5.4, 95% CI .05-60.0).
Table 3 illustrates the prevalence of 1 or more fractures in cases versus controls, stratified by
age group. As expected, in the overall study population, the prevalence of fractures was
higher in the youngest (pre-pubertal) age group, as compared to the middle (pubertal) and
older (post-pubertal) age groups. Additionally, pre-pubertal children with IBD had a higher
fracture risk than matched controls (OR 2.2, 95% CI 1.2-3.8). CD and UC-specific analyses
stratified by age group were not possible due to sample size.
Among IBD patients, we next used geographical region as a surrogate indicator of vitamin D
deficiency and assessed whether the risk of fracture was higher in residents in the Northeast/
Midwest versus the South. We found an increased risk of fractures in the Northeast/
Midwest, though this did not reach statistical significance (OR 1.3, 95% CO 0.8-2.2). After
stratifying by region, the odds ratios for fracture in IBD patients versus controls in the
Northeast/Midwest were slightly higher than in the south (1.1 versus 0.8), though the 95%
confidence intervals were wide and overlapping (Table 3). The odds ratios for fracture were
similar in the Northeast/Midwest and West. Finally, we compared the mean number of
steroid prescriptions per year between those IBD patients who sustained fracture and those
who did not. Patients with fractures had a mean of 1.6 (s.d. 3.5) prescriptions/year for oral
steroids, as compared to a mean of 1.8 (s.d. 3.6) in patients without fracture (p = 0.6). After
adjusting for geographical region, this comparison remained not statistically significant.
Discussion
In this large, epidemiological study of fracture risk in the pediatric IBD population, we
found that children with IBD are no more likely to have experienced a fracture than age, sex,
and gender-matched controls. However, we did observe a trend toward increased vertebral
fractures, particularly in the CD population. We observed a higher prevalence of fractures
among children less than 12 years of age, as compared to older children, a finding consistent
with prior literature describing the age distribution of pediatric fractures 24, 25. We also
found that the fracture risk associated with IBD appeared to be age-specific. IBD children
less than 12 years of age were at an increased risk of fracture when compared to non-IBD
controls, however, no significant differences were observed in older children.
These findings extend the work of prior studies regarding fracture risk in both pediatric and
adult populations in several ways. First, it comes as no surprise that fracture risk may differ
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in the pediatric population, as compared with the adult population. In adults, bone mass is
largely driven by the balance of bone resorption by osteoclast activity relative to bone
formation by osteoblast activity. In children, however, bone mass is driven not only by this
process of remodeling, but also by new bone formation which occurs through a combination
of linear growth and bone modeling. Thus, one might expect the effects of IBD on skeletal
health to be different in children and adults.19 Furthermore, within the adult population, it
appears that fracture risk is greatest in the elderly population,14 further illustrating the
concept that the effect of IBD on skeletal outcomes is an age-dependent process. Although
no systematic studies of fracture risk in the pediatric population have been previosulsy
published19, the results of a recent retrospective study by Persad et al are consistent with the
findings observed here. Persad et al surveyed parents of children with IBD to ascertain the
prevalence of fractures in IBD patients, and unaffected siblings. Although limited by poor
response rates and small sample size, this study also found no significant differences in
fracture prevalence between IBD patients and their sibling controls.
Perhaps the most interesting finding in this current study was the trend toward increased
vertebral fractures in IBD patients, and particularly those with Crohn's disease. Indeed,
vertebral fractures are the most common form of osteoporosis-related fractures in the
pediatric population, and have been reported in children with Crohn's disease.26 Although
the effect estimates were relatively strong (OR 2.7 for IBD overall, and 5.4 for CD), even
the relatively large sample size of this study (1242 patients with IBD, 737 CD) did not
provide adequate power to detect a significant association owing to the rarity of this
outcome. Additionally, this study did not allow for the ascertainment of subclinical vertebral
fractures, which are not uncommon in young adults with IBD27.
A second notable finding in this study was the nonsignificant trend towards increased
fracture prevalence in IBD patients from the Northeast and Midwest, as compared with the
South. The risk of fracture in IBD patients versus controls followed a similar pattern.
Although limited by the ecological nature of this analysis, we speculate that this may be a
result of higher prevalence of vitamin D deficiency in northern latitudes21. Surprisingly, we
did not find an association between corticosteroid use and fracture risk. This finding is
consistent with a recent study using peripheral quantitative computed tomography to assess
bone mass in an incident cohort of children with Crohn's disease. This study also found that
glucocorticoids were not associated with decreases in bone mass.18
The strengths of this study are the large and diverse study population, including a wide
range of health plans of varying size, type, and location. Thus, we believe this study
population to be broadly generalizable to the U.S. commercially insured population. In
addition, the identification of cases and controls from within a commercially insured
population minimizes referral bias.
Several limitations must also be considered when interpreting the results of this study. First,
the cross sectional study design limits the ability to make causal inferences. However, given
that sustaining a fracture is unlikely to affect the risk of developing IBD (or need for
corticosteroid treatment), we do not suspect a significant amount of temporal bias.
Importantly, physical activity is not captured in administrative data. If children with IBD
were less physically active than matched controls, then similar fracture rates would suggest
that children with IBD fracture more easily. An additional limitation inherent to studies
involving administrative data is the possibility of misclassification. We used a stringent case
definition that required either multiple IBD-related health contacts or IBD-specific
pharmaceutical claims to establish a diagnosis of CD or UC. This definition is similar to and
represents a balance between administrative definitions that have been previously validated
in the U.S. and Canada28, 29. Nevertheless, our study may not have identified milder cases
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of IBD and/or fractures that did not seek medical attention or utilize health care services.
The use of pharmacy claims to assess medication exposure has both advantages and
disadvantages. Rather than relying on patient recall which may be inaccurate and/or medical
records which indicate medications prescribed but not necessarily filled, outpatient
pharmacy claims accurately reflect medications that were actually dispensed. However, such
data do not capture adherence, another important indicator of exposure. Nevertheless, the
use of pharmacy data as a measure of corticosteroid exposure has been used and accepted in
many studies of IBD.30, 31 Another limitation is that this study may not have been
sufficiently powered to detect small to moderate differences in fracture risk between cases
and controls, particularly in the CD and UC specific analyses. A final limitation is that the
small number of Medicaid patients and lack of uninsured patients limits the generalizability
of these results to such populations.
In conclusion, in this large epidemiological study, we found no significant differences in the
risk of diagnosed fractures in pediatric IBD patients, as compared with age, gender, and
region matched controls; however, a subanalysis in children less than age 12 demonstrated a
significant positive association between IBD and fracture. These findings underscore the
age-dependent effects of IBD on skeletal health outcomes. Importantly, this study does
suggest the possibility of an increased risk of vertebral fractures, perhaps the most
significant indicator of osteoporosis-related fracture in the pediatric age group.
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Fracture Risk by Site in U.S. Children with IBD. Forest plots depict the prevalence odds
ratios and 95% confidence intervals for fractures occurring at various anatomic sites, as well
as at any site.
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Table 3
Prevalence and risk of sustaining 1 or more fractures among U.S. children with IBD,
stratified by age and geographical region
IBD Cases Controls
Age 0-11
 n 186 515
 # Events 22 32
 Prevalence per 100,000 11,828 5,850
 Odds ratio (95% CI) 2.2 (1.2-3.8)
Age 12-17
 n 725 1938
 # Events 69 206
 Prevalence per 100,000 9,517 10,630
 Odds ratio (95% CI) 0.9 (0.7-1.2)
Age 18-20
 n 331 868
 # Events 19 56
 Prevalence per 100,000 5,740 6,452
 Odds ratio (95% CI) 0.9 (0.5-1.5)
Northeast/Midwest
 n 648 1754
 # Events 62 150
 Prevalence per 100,000 9,568 8,552
 Odds ratio (95% CI) 1.1 (8.8-1.5)
South
 n 337 923
 # Events 24 84
 Prevalence per 100,000 7,122 9,101
 Odds ratio (95% CI) 0.8 (0.5-1.2)
West
 n 257 676
 # Events 24 60
 Prevalence per 100,000 9,339 8,876
 Odds ratio (95% CI) 1.1 (0.6-1.7)
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